Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2015
At a glance
- Drugs Cabozantinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Exelixis
- 09 Nov 2015 Final results including data from expansion cohort, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015 (n=43).
- 19 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 10 Nov 2014 Planned end date changed from 1 Nov 2014 to 1 Jun 2015, as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History